Chonnam Med J.  2018 Jan;54(1):55-62. 10.4068/cmj.2018.54.1.55.

Safety and Efficacy of the Endeavor Resolute® Stent in Patients with Multivessel Disease: The HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial

  • 1Department of Cardiovascular Medicine, Chonnam National University Hospital, Gwangju, Korea.
  • 2Department of Cardiology, Chosun University Hospital, Gwangju, Korea.
  • 3Department of Cardiology, Kwangju Veterans Hospital, Gwangju, Korea.
  • 4Department of Cardiology, Kwangju Christian Hospital, Gwangju, Korea.
  • 5Department of Cardiology, Mokpo Jungang Hospital, Mokpo, Korea.
  • 6Department of Cardiology, Jeonju Presbyterian Medical Center, Jeonju, Korea.
  • 7Department of Cardiology, Chunbuk National University Hospital, Jeonju, Korea.
  • 8Department of Cardiology, Wonkwang University Hospital, Iksan, Korea.
  • 9Department of Cardiology, St. Carollo Hospital, Suncheon, Korea.


The Endeavor Resolute® (ER) is a zotarolimus-eluting stent (ZES) with a biocompatible BioLinx polymer. This study prospectively compared the clinical outcomes of 2 versions of ZES, ER and Endeavor Sprint® (ES), in patients with multivessel disease. A total of 488 patients who underwent multivessel percutaneous coronary intervention (PCI) were divided into 2 groups the ER group (n=288) and the ES group (n=200). The primary endpoint was a composite of major adverse cardiac events (MACE) consisting of death, myocardial infarction, and target vessel revascularization after 12 months. In all patients, the prevalence of diabetes was higher in the ER group (42.7% vs. 31.0%, p=0.009). The rate of post-PCI Thrombolysis in Myocardial Infarction flow grade 3 was higher in the ER group (100.0% vs. 98.0%, p=0.028). There were no between-group differences in the in-hospital, 1-month and 12-month clinical outcomes. In the propensity score matched cohort (n=200 in each group), no differences were observed in the baseline and procedural characteristics. There were no statistical differences in the rates of in-hospital, 1-month and 12-month events (12-month MACE in the ER and ES groups: 6.0% vs. 3.5%, p=0.240, respectively). The safety and efficacy of both versions of ZES were comparable in patients with multivessel disease during a 12-month clinical follow-up.


Coronary Artery Disease; Drug-Eluting Stents; Percutaneous Coronary Intervention

MeSH Terms

Cohort Studies
Coronary Artery Disease
Drug-Eluting Stents
Follow-Up Studies
Multicenter Studies as Topic*
Myocardial Infarction
Percutaneous Coronary Intervention
Propensity Score
Prospective Studies*
Full Text Links
  • CMJ
export Copy
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error